TEM
Tempus AI, Inc. Class A Common StockTEM
TEM
About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Employees: 2,400
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
286% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 21
214% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 14
62% more call options, than puts
Call options by funds: $75.7M | Put options by funds: $46.8M
61% more funds holding
Funds holding: 96 [Q3] → 155 (+59) [Q4]
17% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 7 (+1) [Q4]
8.72% more ownership
Funds ownership: 25.2% [Q3] → 33.92% (+8.72%) [Q4]
18% less capital invested
Capital invested by funds: $2.12B [Q3] → $1.75B (-$374M) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
36%
upside
Avg. target
$62
54%
upside
High target
$74
83%
upside
6 analyst ratings
3 positive
50%
3 neutral
50%
0 negative
0%
Needham Ryan MacDonald 32% 1-year accuracy 26 / 81 met price target | 73%upside $70 | Buy Reiterated | 10 Apr 2025 |
Morgan Stanley Tejas Savant 21% 1-year accuracy 4 / 19 met price target | 48%upside $60 | Overweight Maintained | 6 Mar 2025 |
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target | 36%upside $55 | Neutral Maintained | 4 Mar 2025 |
B of A Securities Michael Ryskin 60% 1-year accuracy 3 / 5 met price target | 48%upside $60 | Neutral Maintained | 3 Mar 2025 |
JP Morgan Rachel Vatnsdal 38% 1-year accuracy 6 / 16 met price target | 36%upside $55 | Neutral Downgraded | 25 Feb 2025 |
Financial journalist opinion
Based on 8 articles about TEM published over the past 30 days
Neutral
Business Wire
1 day ago
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise.
Neutral
PRNewsWire
4 days ago
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
Positive
Zacks Investment Research
1 week ago
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment?
Neutral
Invezz
1 week ago
Is it safe to buy the Tempus AI stock dip now?
Tempus AI stock price remains in a deep bear market as investors worry that the hype that drove it to a record high was ending. The TEM stock initially peaked at $91.40 in February, and has now plunged to a low of $37.2, meaning that it has dropped by 60%.
Positive
Zacks Investment Research
2 weeks ago
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock?
The February 2025 acquisition of Ambry Genetics further expands TEM's genomics capabilities with a West Coast lab and enhanced inherited risk testing.
Neutral
Business Wire
3 weeks ago
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presenting research, all of which highlights the application of AI to support clinicians in delivering personalized care. “Tempus.
Neutral
MarketBeat
3 weeks ago
4 Healthcare Stocks With Massive Gains—and More to Come
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far.
Neutral
Business Wire
3 weeks ago
Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025. Tempus' Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Wednesday, April 9. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medi.
Positive
Zacks Investment Research
1 month ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
Positive
Seeking Alpha
1 month ago
Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Tempus AI's financials have significantly improved, with positive cash flow expected next quarter and strong revenue growth projected for FY25. Q4FY24 saw record revenues, driven by a 35.8% YoY growth, with the Data & Services segment growing by 44.6% YoY. FY24 revenues hit an all-time high of $693.4 million, with major agreements signed and the launch of the AI-enabled health app, Olivia.
Charts implemented using Lightweight Charts™